Mercor
This role requires an expert with a decision-maker’s mindset who has driven translational pharmacology decisions under governance and uncertainty. The expert will write dose rationales, encode decision heuristics into structured guidance, and surface unwritten decision rules used by senior translational leaders.
Key Responsibilities
- • Write “golden” FIH dose rationales and escalation strategies for representative programs.
- • Encode the decision heuristics and trade-offs used by senior translational leaders into structured guidance and rubrics.
- • Surface unwritten decision rules — when and why experienced teams override model-based recommendations.
Required
- • Has owned FIH starting dose, SAD/MAD design, and Phase 2 dose selection for multiple assets.
- • Participated in governance or review boards, defending dose/exposure rationale in front of senior leadership or regulators.
- • Demonstrates ability to balance nonclinical → clinical translation: tox, PK, PD, potency, and MoA.
- • Can articulate the real decision calculus behind dose selection (safety, pharmacology, speed-to-proof).
- • Capable of turning narrative judgment into explicit decision rules and rubrics for AI training and evaluation.
- • 10+ years in major biopharma or biotech or in specialized translational pharmacology consulting.
- • Has personally led FIH dose and/or SAD/MAD escalation for ≥2–3 assets.
- • Proven governance experience: IND sign-off, dose justification memos, exposure–response presentations.
- • CV or track record includes statements like “led clinical pharmacology strategy and FIH dose selection” or “accountable for exposure–response in Phase 1/2.”
- • Avoid pure modeling profiles; the ideal expert has decision accountability, not just analytical skill.
Company Overview
Industry: Healthcare Technology
Company Size: 500-1,000 employees
Founded: 2015
Headquarters: San Francisco, CA
Company Links
Key Contacts
Contact information not available
About the Company
Leading healthcare technology company focused on improving patient outcomes through innovative digital solutions. We're transforming the way healthcare is delivered with cutting-edge technology and data-driven insights. Our platform serves over 10,000 healthcare professionals and has processed millions of patient interactions.
Recent News & Updates
Who We’re Looking For
- Has owned FIH starting dose, SAD/MAD design, and Phase 2 dose selection for multiple assets.
- Participated in governance or review boards, defending dose/exposure rationale in front of senior leadership or regulators.
- Demonstrates ability to balance nonclinical → clinical translation: tox, PK, PD, potency, and MoA.
- Can articulate the real decision calculus behind dose selection (safety, pharmacology, speed-to-proof).
- Capable of turning narrative judgment into explicit decision rules and rubrics for AI training and evaluation.
- :10+ years in major biopharma or biotech (e.g., Lilly, Roche, AbbVie, Amgen, Novartis, GSK, Regeneron, Vertex, Incyte, Gilead) or in specialized translational pharmacology consulting.
- Has personally led FIH dose and/or SAD/MAD escalation for ≥2–3 assets.
- Proven governance experience: IND sign-off, dose justification memos, exposure–response presentations.
- CV or track record includes statements like “led clinical pharmacology strategy and FIH dose selection” or “accountable for exposure–response in Phase 1/2.”
- Avoid pure modeling profiles; the ideal expert has decision accountability, not just analytical skill.
- Write “golden” FIH dose rationales and escalation strategies for representative programs.
- Encode the decision heuristics and trade-offs used by senior translational leaders into structured guidance and rubrics.
- Surface unwritten decision rules — when and why experienced teams override model-based recommendations.
- Representative drug programs or data packets (GLP tox summaries, PK/PD tables, potency & MoA context).
- Target prompts for translational decision-making (e.g., “Recommend FIH dose and escalation strategy given these data”).
- Golden Decision Memos: exemplar dose justification memos that reflect the level of reasoning and format expected from top-tier translational pharmacologists.
- Decision Rubrics: scoring guides capturing acceptable vs. unsafe dose rationales, missed edge cases, or failure modes.
- Meta-Layer Commentary: short narrative explaining unspoken heuristics — how senior teams weigh risk tolerance, potency data, or tox uncertainty.
Keep track of your job search
Save personal notes for each job to track your thoughts, application status, and follow-ups.
Try for freeUpload your resume
Sign up to upload your resume and get AI-powered customization for job applications.
Sign up freePractice your interview
Get AI-powered mock interviews tailored to this PK/PD Module expert: Translational / Clinical Pharmacology Decision-Maker role. Upload your resume and practice with real-time voice feedback.
Sign up to practice